Lilly hikes revenue forecasts on booming obesity drug sales

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Dive Brief: Tirzepatide, sold as Zepbound for obesity and Mounjaro for diabetes, became the world’s best-selling drug in the third quarter, helping spur Eli Lilly to raise its full-year forecasts. Zepbound and Mounjaro brought in a combined $10.1 billion in the period, up from $4.37 billion in the third quarter of last year, Lilly said Thursday. The franchis ...